Trial · NCT02183025
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of severity of lumbar and/or abdominal pain on a visual analogue scale (VAS) | Baseline and day 3-5 of each treatment cycle | |
| Secondary | Final global assessment of efficacy by patient on a 4-point scale | day 3-5 of the second treatment cycle | |
| Secondary | Final global assessment of efficacy by investigator on a 4-point scale | day 3-5 of the second treatment cycle | |
| Secondary | Final global assessment of tolerability by patient on a 4-point scale | day 3-5 of the second treatment cycle | |
| Secondary | Final global assessment of tolerability by investigator on a 4-point scale | day 3-5 of the second treatment cycle | |
| Secondary | Number of Participants with Adverse Events (AE) | Up to 4 weeks after last treatment cycle | |
| Secondary | Incidence of significant laboratory events | Up to 4 weeks after last treatment cycle | |
| Secondary | Number of perforations, ulcerations and/or bleedings (PUB) of the upper gastro-intestinal tract | Up to 4 weeks after last treatment cycle | |
| Secondary | Number of gastro-intestinal adverse events (GI-AEs) | Up to 4 weeks after last treatment cycle | |
| Secondary | Duration of hospitalization stay due to GI-AEs | Up to 4 weeks after last treatment cycle | |
| Secondary | Number of additional visits at physician due to GI-AEs | Up to 4 weeks after last treatment cycle | |
| Secondary | Duration of hospitalization due to drug related AEs | Up to 4 weeks after last treatment cycle | |
| Secondary | Number of withdrawals due to AEs | Up to 4 weeks after last treatment cycle | |
| Secondary | Intensity of AEs on a 3-point scale | Up to 4 weeks after last treatment cycle | |
| Secondary | Evaluation of labor and/or daily life disability associated with dysmenorrhea on a VAS | Baseline and day 3-5 of each treatment cycle | |
| Secondary | Change in severity of symptomatology associated with dysmenorrhea | Baseline and day 3-5 of each treatment cycle |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02183025/registered